Interferon in the treatment of ill adults with Covid-19 in the Republic of Guinea

IF 0.8 4区医学 Q3 MEDICINE, GENERAL & INTERNAL

African Health Sciences Pub Date : 2023-07-13 DOI:10.4314/ahs.v23i2.6

Valentín Santiago Rodríguez Moya, Ladys Alfonso Águila, Nohuou Mangué Camara, Sékuo Ditinn Cisse, Doukure Mamady, Sakoba Keïta, Kava Mamady Bakary, Lianet Díaz Pérez, Elaine Díaz Casañas

{"title":"Interferon in the treatment of ill adults with Covid-19 in the Republic of Guinea","authors":"Valentín Santiago Rodríguez Moya, Ladys Alfonso Águila, Nohuou Mangué Camara, Sékuo Ditinn Cisse, Doukure Mamady, Sakoba Keïta, Kava Mamady Bakary, Lianet Díaz Pérez, Elaine Díaz Casañas","doi":"10.4314/ahs.v23i2.6","DOIUrl":null,"url":null,"abstract":"Background: Effective and safe antiviral treatments are required to refrain the COVID-19. Objectives: Investigate the efficacy and safety of interferon in the treatment of COVID-19. Methods: The inclusion criteria were patients who gave their signed consent, with detection confirmed by RT-PCR of SARSCoV- 2, 18 years and older. Patients received therapy as per the Guinea COVID-19 protocol in the group B; the group A received the same treatment including administration of interferon. The outcome measures the time to negative conversion of SARSCoV- 2, mortality, patients transferred to ICU and safety, according to the reports of adverse events. Results: 345 patients were included, 171 in the group A and 174 in the group B. After the treatments, the RT-PCR negative results were attained in the patients in the group A in 9.15±4.79 days and in those in the group B in 14.83±6.67 days. No patient in the group A had to be transferred to ICU, and they all survived; in the group B, 26 patients were transferred to ICU and six of them died. There were eight adverse events with causality relation with interferon administration. Conclusions: The interferon resulted effective and safe in contributing to the viral replication conversion to negative results in shorter time and to survival. Keywords: SARS-Cov-2; COVID 19; zoonosis; human recombinant interferon.","PeriodicalId":7853,"journal":{"name":"African Health Sciences","volume":null,"pages":null},"PeriodicalIF":0.8000,"publicationDate":"2023-07-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"African Health Sciences","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.4314/ahs.v23i2.6","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Effective and safe antiviral treatments are required to refrain the COVID-19. Objectives: Investigate the efficacy and safety of interferon in the treatment of COVID-19. Methods: The inclusion criteria were patients who gave their signed consent, with detection confirmed by RT-PCR of SARSCoV- 2, 18 years and older. Patients received therapy as per the Guinea COVID-19 protocol in the group B; the group A received the same treatment including administration of interferon. The outcome measures the time to negative conversion of SARSCoV- 2, mortality, patients transferred to ICU and safety, according to the reports of adverse events. Results: 345 patients were included, 171 in the group A and 174 in the group B. After the treatments, the RT-PCR negative results were attained in the patients in the group A in 9.15±4.79 days and in those in the group B in 14.83±6.67 days. No patient in the group A had to be transferred to ICU, and they all survived; in the group B, 26 patients were transferred to ICU and six of them died. There were eight adverse events with causality relation with interferon administration. Conclusions: The interferon resulted effective and safe in contributing to the viral replication conversion to negative results in shorter time and to survival. Keywords: SARS-Cov-2; COVID 19; zoonosis; human recombinant interferon.

查看原文本刊更多论文

干扰素在几内亚共和国治疗患有 Covid-19 的成人病人中的应用

背景：需要有效、安全的抗病毒治疗来抑制 COVID-19。研究目的研究干扰素治疗 COVID-19 的有效性和安全性。方法纳入标准：患者签字同意，经 RT-PCR 检测证实感染 SARSCoV- 2，年龄在 18 岁及以上。B 组患者按照几内亚 COVID-19 方案接受治疗；A 组患者接受相同的治疗，包括使用干扰素。根据不良事件报告，结果衡量了 SARSCoV- 2 阴转的时间、死亡率、转入重症监护室的患者人数和安全性。研究结果治疗后，A 组患者在（9.15±4.79）天内达到 RT-PCR 阴性结果，B 组患者在（14.83±6.67）天内达到 RT-PCR 阴性结果。A 组患者无一转入重症监护室，全部存活；B 组有 26 名患者转入重症监护室，其中 6 人死亡。有 8 例不良事件与干扰素用药存在因果关系。结论干扰素能有效、安全地促使病毒复制在较短时间内转为阴性，并使患者存活。关键词SARS-Cov-2；COVID 19；人畜共患病；人重组干扰素。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

African Health Sciences MEDICINE, GENERAL & INTERNAL-

CiteScore

2.30

自引率

0.00%

发文量

179

审稿时长

>12 weeks

期刊介绍： The African Health Sciences is an internationally refereed journal publishing original articles on research, clinical practice, public health, policy, planning, implementation and evaluation, in the health and related sciences relevant to Africa and the tropics. Its objectives are to: Advocate for and promote the growth of reading culture in sub Saharan Africa; Provide a high quality journal in which health and policy and other researchers and practitioners in the region can and world wide, can publish their work; Promote relevant health system research and publication in the region including alternative means of health care financing, the burden of and solution of health problems in marginalized urban and rural communities amongst the displaced and others affected by conflict; Promote research and the systematic collection and collation and publication of data on diseases and conditions of equity and influence; Promote development of evidence-based policies and guidelines for clinical, public health and other practitioners. African Health Sciences acknowledges support provided by the African Health Journals Partnership Project that is funded by the US National Institutes of Health (through the National Library of Medicine and the Fogarty International Center) and facilitated by the Council of Science Editors.